• 1
    Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 1977; 146: 85768.
  • 2
    Enokida M, Yamasaki D, Okano T, Hagino H, Morio Y, Teshima R. Bone mass changes of tibial and vertebral bones in young and adult rats with collagen-induced arthritis. Bone 2001; 28: 8793.
  • 3
    Yamasaki D, Enokida M, Okano T, Hagino H, Teshima R. Effects of ovariectomy and estrogen replacement therapy on arthritis and bone mineral density in rats with collagen-induced arthritis. Bone 2001; 28: 63440.
  • 4
    Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BAC, Valkema R, Westedt ML, et al. Increased bone mass with pamidronate treatment in rheumatoid arthritis: results of a three-year randomized, double-blind trial. Arthritis Rheum 1996; 39: 396402.
  • 5
    Nakamura M, Ando T, Abe M, Kumagai K, Endo Y. Contrast between effects of aminobisphosphonate and non-aminobisphosphonate on collagen-induced arthritis in mice. Br J Pharmacol 1996; 119: 20512.
  • 6
    Takaoka Y, Nagai H, Mori H, Takahashi N. The effect of TRK-530 on experimental arthritis in mice. Biol Pharm Bull 1997; 20: 114750.
  • 7
    Osterman T, Virtamo T, Lauren L, Kippo K, Pasanen I, Hannuniemi R, et al. Slow-release clodronate in prevention of inflammation and bone loss associated with adjuvant arthritis. J Pharmacol Exp Ther 1997; 280: 10017.
  • 8
    Osterman T, Kippo K, Lauren L, Hannuniemi R, Sellman R. Effect of clodronate on established adjuvant arthritis. Rheumatoid Int 1994; 14: 13947.
  • 9
    Muller K, Wiesenberg I, Jaeggi K, Green JR. Effects of the bisphosphonate zoledronate on bone loss in the ovariectomized and in the adjuvant arthritic rat. Arzneimittelforschung 1998; 48: 816.
  • 10
    Flora L. Comparative antiinflammatory and bone protective effects of two diphosphonates in adjuvant arthritis. Arthritis Rheum 1979; 22: 3406.
  • 11
    Osterman T, Kippo K, Lauren L, Pasanen I, Hannuniemi R, Sellman R. A comparison of clodronate and indomethacin in the treatment of adjuvant arthritis. Inflamm Res 1997; 46: 7985.
  • 12
    Takanashi M, Funaba Y, Ito M, Kawabe N, Nakadate-Matsushita T. Inhibitory effects of TRK-530 on rat adjuvant arthritis. Pharmacology 1998; 56: 24251.
  • 13
    Osterman T, Kippo K, Hannuniemi R, Sellman R. Effect of clodronate on established collagen-induced arthritis in rats. Inflamm Res 1995; 44: 25863.
  • 14
    Zhao H, Shuto T, Hirata G, Iwamoto Y. Aminobisphosphonate (YM175) inhibits bone destruction in rat adjuvant arthritis. J Orthop Sci 2000; 5: 397403.
  • 15
    Takahashi M, Koike J, Kawabe N, Nakadate-Matsushita T. Inhibitory effect of TRK-530 on inflammatory cytokines in bone marrow of rats with adjuvant arthritis. Pharmacology 1998; 56: 23741.
  • 16
    Francis MD, Hovancik K, Boyce RW. NE-58095: a diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. Int J Tissue React 1989; 11: 23952.
  • 17
    Dunn CJ, Doyle DV, Willoughby DA. Investigation of the acute and chronic anti-inflammatory properties of diphosphonate using a broad spectrum of immune and non-immune inflammatory reactions. Drug Dev Res 1993; 28: 4755.
  • 18
    Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BAC, Breedveld FC. Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study. J Rheumatol 1994; 21: 201620.
  • 19
    Maccagno A, Di Giorgio E, Roldan EJ, Caballero LE, Perez Lloret A. Double blind radiological assessment of continuous oral pamidronic acid in patients with rheumatoid arthritis. Scand J Rheumatol 1994; 23: 2114.
  • 20
    Tan PLJ, Ames R, Yeoman S, Ibbertson HK, Caughey DE. Effects of aminobisphosphonate infusion on biochemical indices of bone metabolism in rheumatoid arthritis. Br J Rheumatol 1989; 28: 3258.
  • 21
    Engelhardt G, Homma D, Schnitzler C. Meloxicam: a potent inhibitor of adjuvant arthritis in the Lewis rat. Inflamm Res 1995; 44: 54855.
  • 22
    Gasser JA. Assessing bone quantity by pQCT. Bone 1995; 17 Suppl 4: 145S–54S.
  • 23
    Sato M. Comparative x-ray densitometry of bones from ovariectomized rats. Bone 1995; 17 Suppl 4: 157S–62S.
  • 24
    Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res 1987; 2: 595610.
  • 25
    Jee WS, Mori S, Li XJ, Chan S. Prostaglandin E2 enhances cortical bone mass and activates intracortical bone remodeling in intact and ovariectomized female rats. Bone 1990; 11: 25366.
  • 26
    Fleisch H. Bisphosphonates: preclinical. In: FleischH, editor. Bisphosphonates in bone disease: from the laboratory to the patient. New York: Academic Press; 2000. p. 2766.
  • 27
    Morii H, Nishizawa Y, Taketani Y, Nakamura T, Itabashi A, Mizunuma H, et al. A randomized controlled trial with ONO-5920 (minodronate/YM529) in Japanese patients with postmenopausal osteoporosis [abstract]. J Bone Miner Res 2002; 17 Suppl 1: S471.
  • 28
    Yoshida Y, Morita A, Kitamura K, Inazu M, Okimoto N, Okazaki Y, et al. Responses of trabecular and cortical bone turnover and bone mass and strength to bisphosphonate YH529 in ovariohysterectomized beagles with calcium restriction. J Bone Miner Res 1998; 13: 101122.
  • 29
    Virtama P, Helela T, Kalliomaki JL. Osteoporosis in rheumatoid arthritis: a follow-up study. Acta Rheumatol Scand 1968; 14: 27684.
  • 30
    Moran EL, Fornasier TL, Bogoch TR. Pamidronate prevents bone loss associated with carrageenan arthritis by reducing resorptive activity but not recruitment of osteoclasts. J Orthop Res 2000; 18: 87381.
  • 31
    Podworny NV, Kandel RA, Renlund RC, Grynpas MD. Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis. J Rheumatol 1999; 26: 197282.
  • 32
    Hayashida K, Ochi T, Fujimoto M, Owaki H, Shimaoka Y, Ono K, et al. Bone marrow changes in adjuvant-induced and collagen-induced arthritis: interleukin-1 and interleukin-6 activity and abnormal myelopoiesis. Arthritis Rheum 1992; 35: 2415.
  • 33
    Cantatore FP, Acquista CA, Pipitone V. Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. J Rheumatol 1999; 26: 231823.
  • 34
    Fujimoto M, Hayashida K, Ochi T, Owaki H, Shimaoka Y, Okamura M, et al. Fluctuation of interleukin-1 and -6 activity in bone marrow serum in collagen-induced arthritis in rats. Biomed Res 1992; 13: 24351.
  • 35
    Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000; 17: 27586.
  • 36
    Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 2000; 18: 485864.
  • 37
    Fujimoto M, Ochi T, Owaki H, Wakitani S, Suzuki R, Takai M, et al. Elevated activity of interleukins-1, -2, and -3 in the bone marrow of collagen-induced arthritic rats. Biomed Res 1988; 9: 4017.
  • 38
    Szekanecz Z, Halloran MM, Volin MV, Woods JM, Strieter RM, Haines KG III, et al. Temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis. Arthritis Rheum 2000; 43: 126677.
  • 39
    Bogoch E, Gschwend N, Bogoch B, Rahn B, Perren S. Juxtaarticular bone loss in experimental inflammatory arthritis. J Orthop Res 1988; 6: 64856.
  • 40
    Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Monkkonen J, et al. Molecular mechanisms of action of bisphosphonates. Bone 1999; 24 Suppl 5: 73S–9S.